With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world... Show more
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NVO declined for three days, in of 274 cases, the price declined further within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
NVO moved below its 50-day moving average on July 28, 2025 date and that indicates a change from an upward trend to a downward trend.
The Aroon Indicator for NVO entered a downward trend on July 28, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NVO's RSI Indicator exited the oversold zone, of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 13, 2025. You may want to consider a long position or call options on NVO as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for NVO just turned positive on August 14, 2025. Looking at past instances where NVO's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVO advanced for three days, in of 334 cases, the price rose further within the following month. The odds of a continued upward trend are .
NVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.606) is normal, around the industry mean (8.904). P/E Ratio (13.052) is within average values for comparable stocks, (23.460). Projected Growth (PEG Ratio) (1.476) is also within normal values, averaging (1.835). Dividend Yield (0.032) settles around the average of (0.028) among similar stocks. P/S Ratio (4.649) is also within normal values, averaging (3.346).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a developer of pharmaceutical products
Industry PharmaceuticalsMajor
A.I.dvisor indicates that over the last year, NVO has been closely correlated with NONOF. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVO jumps, then NONOF could also see price increases.
Ticker / NAME | Correlation To NVO | 1D Price Change % | ||
---|---|---|---|---|
NVO | 100% | +0.10% | ||
NONOF - NVO | 70% Closely correlated | +0.38% | ||
TECH - NVO | 36% Loosely correlated | -1.77% | ||
GMAB - NVO | 35% Loosely correlated | +1.37% | ||
BCAB - NVO | 33% Loosely correlated | -7.21% | ||
MRK - NVO | 32% Poorly correlated | +0.06% | ||
More |
Ticker / NAME | Correlation To NVO | 1D Price Change % |
---|---|---|
NVO | 100% | +0.10% |
Pharmaceuticals: Major industry (61 stocks) | 40% Loosely correlated | +0.49% |
Pharmaceuticals industry (393 stocks) | 31% Poorly correlated | -0.29% |